Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Congress Sessions cont’d<br />
n Inhibitor Incidence <strong>in</strong> Hemophilia A Patients<br />
Intensively Treated with Cont<strong>in</strong>uous Infusion<br />
of Factor VIII<br />
Batorova A1 , Holme P2 , Gr<strong>in</strong>geri A3 , Fijnvandraat<br />
K4 , Richards M5 , Hermans C6 , Altisent C7 , Lopez-<br />
Fernández M8 on behalf of the European<br />
Hemophilia Treatment Standardization Board<br />
(EHTSB)<br />
1National Hemophilia Center, Dept. of<br />
Hematology and Transfusion Medic<strong>in</strong>e, University<br />
Hospital, Bratislava, Slovakia, 2Haematology Medical Department, Rikshospitalet, University<br />
Hospital, Oslo, Norway, 3Centro Emofilia A.<br />
Bianchi Bonomi, University Hospital, Milan, Italy,<br />
4Department of Pediatric Hematology, Academic<br />
Medical Center, Amsterdam, the Netherlands,<br />
5Paediatric Haematology Department, Children’s<br />
Day Hospital, St. James University Hospital,<br />
Leeds, United K<strong>in</strong>gdom, 6Haemostasis Department, Cl<strong>in</strong>iques Universitaires St Luc,<br />
Bruxelles, Belgium, 7Servicio de Hematologia –<br />
Unidad de Hemofilia, Hospital Val d’ Hebron,<br />
Barcelona, 8Thrombosis and Haemostasis Unit.<br />
Servicio de Hematología y Hemoterapia,<br />
Complexo Hospitalario Universitario de A<br />
Coruña, Coruña, Spa<strong>in</strong><br />
n Factor VIII Light Cha<strong>in</strong> Mutations and Cyste<strong>in</strong>e<br />
Substitutions Predispose for Inhibitor<br />
Development <strong>in</strong> Mild and Moderate<br />
Hemophilia A: First Results From the<br />
INSIGHT Study<br />
Eckhardt CL1 , 2 , Peters M1 , Kamphuisen PW2 ,<br />
Astermark J3 , Oldenburg J4 , Hay CRM5 ,<br />
Santagost<strong>in</strong>o E6 , Ingerslev J7 , D’Oiron R8 , van der<br />
Bom JG9 and Fijnvandraat K1 for the INSIGHT<br />
<strong>in</strong>vestigators<br />
1Paediatric Haematology, Emma Children’s<br />
Hospital, Amsterdam, the Netherlands, 2Vascular Medic<strong>in</strong>e, Academic Medical Center,<br />
Amsterdam, the Netherlands, 3Centre for<br />
Thrombosis and Haemostasis, Malmö University<br />
Hospital, Lund University, Malmö, Sweden,<br />
4Institute of Experimental Haematology and<br />
Transfusion Medic<strong>in</strong>e, University Hospital Bonn,<br />
Bonn, Germany, 5Hemophilia Center, Manchester<br />
Royal Infirmary, Manchester, U.K., 6Angelo Bianchi Bonomi Hemophilia and Thrombosis<br />
Center, IRCCS Maggiore Hospital, Mangiagalli &<br />
Reg<strong>in</strong>a Elena Foundation, University of Milan,<br />
Milan, Italy, 7University Hospital Skejby, Aarhus,<br />
Denmark, 8Haemophilia Centre, Hôpital Bicêtre,<br />
Paris, France, 9Cl<strong>in</strong>ical Epidemiology, Leiden<br />
University Medical Center, Leiden, the<br />
Netherlands<br />
n Inhibitor Incidence <strong>in</strong> Previously Untreated<br />
Patients (PUPs) with Hemophilia A and B -<br />
<strong>F<strong>in</strong>al</strong> Evaluation of the Prospective PUP Study<br />
Conducted by the Paediatric Committee of<br />
the GTH (German, Swiss, and Austrian Society<br />
of Thrombosis and Haemostasis Research)<br />
Kreuz W1 , Auerswald G2 , Budde U3 , Lenk H4 ,<br />
Escuriola Ett<strong>in</strong>gshausen C1, on behalf of GTH-<br />
PUP-Study-Group<br />
1JW Goethe University Hospital, Dept. Pediatrics<br />
III, Frankfurt, 2ZKH St.Jürgen-Straße, Prof. Hess<br />
Childrens Hospital, Bremen, 3AescuLaboratory, Hamburg, 4University Hospital Leipzig, Dept.<br />
Pediatrics, Germany<br />
n First Human Dose Trial of Subcutaneously<br />
Adm<strong>in</strong>istered Recomb<strong>in</strong>ant Activated Factor<br />
VII (rFVIIa) to Hemophilia A and B Patients<br />
Shows Prolonged FVIIa Half-Life, and Provides<br />
Evidence of Safety and Tolerability<br />
Tiede A1 , Lethagen S2 , Friedrich U3 , Stenmo C3 ,<br />
Allen G4 , Giangrande P5 , Goudemand J6 , Hay C7 ,<br />
Holmström M8 , Klamroth R9 , McKenzie S10 ,<br />
Miesbach W11 , Negrier C12 , Jimenez Yuste V13 and<br />
Berntorp E14 1Hannover Medical School, Hannover, Germany,<br />
2 3 Rigshospitalet, Copenhagen, Denmark, Novo<br />
Nordisk A/S, Bagsvaerd, Denmark, 4Children’s Memorial Hospital, Chicago, U.S.A., 5Churchill Hospital, Oxford, U.K., 6Hôpital Cardiologique,<br />
Lille Cedex, France, 7Manchester Royal Infirmary,<br />
Manchester, U.K., 8Karol<strong>in</strong>ska Universitetssjukhuset, Stockholm, Sweden,<br />
9Vivantes Kl<strong>in</strong>ikum im Friedrichsha<strong>in</strong>, Berl<strong>in</strong>,<br />
Germany, 10Thomas Jefferson University,<br />
Philadelphia, U.S.A., 11Institut für<br />
Transfusionsmediz<strong>in</strong> Universitätskl<strong>in</strong>ikum<br />
Frankfurt, Germany, 12Hôpital Edouard Herriot,<br />
Lyon, France, 13Hospital Universitario La Paz,<br />
Madrid, Spa<strong>in</strong>, 14Universitetssjukhuset MAS,<br />
Malmö, Sweden<br />
n Why Is the Frequency of Inhibitors Increas<strong>in</strong>g<br />
Among Swedish Children with Severe<br />
Hemophilia A?<br />
Ljung R1 , Petr<strong>in</strong>i P2 , Holmberg F1 1Lund University, Departments of Paediatrics and<br />
Malmö Centre for Thrombosis and Haemostasis,<br />
University Hospital, Malmö, Sweden and<br />
2Paediatric Department of Coagulation<br />
Disorders, Karol<strong>in</strong>ska University Hospital,<br />
Stockholm, Sweden<br />
35<br />
Wednesday, July 14. 2010